NeuBase Therapeutics, Inc. (NBSE) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NeuBase Therapeutics, Inc. (NBSE) Healthcare & Pipeline Overview

NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company specializing in therapies for rare genetic diseases and cancers, utilizing its proprietary PATrOL platform to target mutant genes. The company focuses on addressing Huntington's disease, myotonic dystrophy, and KRAS-mutated cancers, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for NBSE?

NeuBase Therapeutics, Inc. presents a high-risk, high-reward investment opportunity due to its pre-clinical stage and focus on novel therapies for rare genetic diseases and cancers. The company's proprietary PATrOL platform offers a unique approach to targeting mutant genes, potentially addressing diseases with limited treatment options. Key value drivers include the successful advancement of lead programs NT0100, NT0200, and NT0300 through clinical trials, securing regulatory approvals, and establishing partnerships with larger pharmaceutical companies. Upcoming catalysts include the initiation of Phase 1 clinical trials for NT0100 in Huntington's disease, anticipated to begin in late 2026 or early 2027, and the progression of NT0200 and NT0300 through preclinical development. The company's valuation is highly dependent on the clinical trial outcomes and regulatory milestones. Potential risks include clinical trial failures, regulatory setbacks, competition from other gene therapy companies, and the need for additional funding to support ongoing research and development. A successful outcome could result in significant returns, while failure could lead to substantial losses.

Based on FMP financials and quantitative analysis

NBSE Key Highlights

• NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company focused on developing therapies for rare genetic diseases and cancers.
• The company's proprietary PATrOL platform targets mutant genes, offering potential treatments for conditions like Huntington's disease and myotonic dystrophy.
• Lead programs include NT0100 for Huntington's disease, NT0200 for myotonic dystrophy type 1, and NT0300 for KRAS-mutated cancers.
• NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania, where its research and development activities are concentrated.
• The company's market capitalization is $0.00B, reflecting its pre-clinical stage and speculative valuation.

Who Are NBSE's Competitors?

NBSE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NBSE's Key Strengths?

• Proprietary PATrOL platform technology.
• Focus on rare genetic diseases with high unmet medical needs.
• Strong intellectual property protection for its therapies.
• Experienced management team with expertise in drug development.

What Are NBSE's Weaknesses?

• Pre-clinical stage company with no approved products.
• Limited financial resources.
• High dependence on the success of its lead programs.
• Lack of commercialization experience.

What Could Drive NBSE Stock Higher?

• Initiation of Phase 1 clinical trials for NT0100 in Huntington's disease (anticipated in late 2026 or early 2027).
• Progression of NT0200 through preclinical development.
• Advancement of NT0300 through preclinical studies.
• Potential strategic partnerships with larger pharmaceutical companies.

What Are the Key Risks for NBSE?

• Financial-distress signal — its Altman Z-Score of -10.58 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-88.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for NT0100, NT0200, or NT0300.
• Regulatory setbacks in obtaining approvals from the FDA or EMA.
• Competition from other gene therapy companies.
• Need for additional funding to support ongoing research and development.
• Intellectual property challenges or infringement claims.

What Are the Growth Opportunities for NBSE?

• Expansion into New Therapeutic Areas: NeuBase Therapeutics has the opportunity to leverage its PATrOL platform to develop therapies for additional rare genetic diseases and cancers. By expanding its pipeline, the company can diversify its risk and increase its potential market reach. The market for rare disease therapies is projected to reach $258.7 billion by 2028, growing at a CAGR of 11.4% from 2021. This growth is driven by increasing awareness of rare diseases and the development of new diagnostic tools. Timeline: Ongoing, with new programs initiated as research progresses.
• Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies can provide NeuBase with access to additional funding, expertise, and resources to accelerate the development and commercialization of its therapies. Collaborations can also help the company expand its market reach and access new patient populations. The value of pharmaceutical collaborations and licensing deals reached $447 billion in 2023. Timeline: Ongoing, with potential partnerships to be established as programs advance through clinical trials.
• Advancement of Lead Programs Through Clinical Trials: The successful completion of clinical trials for NT0100, NT0200, and NT0300 is critical to the company's growth and valuation. Positive clinical trial results can lead to regulatory approvals and commercialization, generating significant revenue for the company. The global market for Huntington's disease therapeutics is projected to reach $1.4 billion by 2028. Timeline: Upcoming, with Phase 1 clinical trials for NT0100 anticipated to begin in late 2026 or early 2027.
• Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA and EMA is essential for the commercialization of NeuBase's therapies. Regulatory approvals can provide the company with market exclusivity and generate significant revenue. The cost to bring a new drug to market is estimated to be $2.6 billion, including the cost of clinical trials and regulatory submissions. Timeline: Dependent on clinical trial outcomes, with potential approvals expected in the late 2020s or early 2030s.
• Expansion into Personalized Medicine: NeuBase Therapeutics can leverage its PATrOL platform to develop personalized therapies tailored to individual patients based on their specific genetic mutations. Personalized medicine is a rapidly growing field, with the global market projected to reach $4.2 trillion by 2030. This growth is driven by advancements in genomics and proteomics, as well as the increasing availability of personalized diagnostic tools. Timeline: Long-term, with potential applications to be explored as the company's platform matures.

What Opportunities Does NBSE Have?

• Expansion into new therapeutic areas.
• Strategic partnerships with larger pharmaceutical companies.
• Advancement of lead programs through clinical trials.
• Securing regulatory approvals for its therapies.

What Threats Does NBSE Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from other gene therapy companies.
• Need for additional funding to support ongoing research and development.

What Are NBSE's Competitive Advantages?

• Proprietary PATrOL platform technology.
• Focus on rare genetic diseases with limited treatment options.
• Strong intellectual property protection for its therapies.
• First-mover advantage in developing PATrOL-based therapies.

What Does NBSE Do?

NeuBase Therapeutics, Inc., established as a pre-clinical-stage biopharmaceutical company, is dedicated to the development of innovative therapies for rare genetic diseases and various forms of cancer. The company's core technology revolves around its proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform, which is engineered to target and neutralize mutant genes responsible for these diseases. Founded with the vision of addressing unmet medical needs in genetic disorders and oncology, NeuBase has strategically focused its research and development efforts on specific disease areas with significant patient populations and limited treatment options. The company's lead programs are designed to address Huntington's disease (HD), myotonic dystrophy type 1 (DM1), and cancers driven by mutations in the KRAS gene. NT0100, a PATrOL-enabled anti-gene therapy, is being developed for the treatment of Huntington's disease, a progressive neurodegenerative disorder. NT0200, another PATrOL-enabled anti-gene therapy, targets myotonic dystrophy type 1, a form of muscular dystrophy. NT0300 is a PATrOL-enabled therapeutic designed to target the mutated KRAS gene, which is implicated in various cancers. NeuBase Therapeutics operates primarily from its headquarters in Pittsburgh, Pennsylvania, where its research and development activities are concentrated. As a pre-clinical-stage company, NeuBase is focused on advancing its lead programs through preclinical studies and preparing for clinical trials. The company's long-term success depends on the successful development and commercialization of its PATrOL-based therapies, as well as its ability to secure regulatory approvals and establish strategic partnerships.

What Products and Services Does NBSE Offer?

• Develop therapies for rare genetic diseases.
• Focus on treating cancers caused by mutant genes.
• Utilize a proprietary PATrOL platform to target mutant genes.
• Develop anti-gene therapies for Huntington's disease (NT0100).
• Develop anti-gene therapies for myotonic dystrophy type 1 (NT0200).
• Develop therapeutic treatments targeting the mutated KRAS gene (NT0300).

How Does NBSE Make Money?

• Develops proprietary therapies based on the PATrOL platform.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties on sales of approved therapies.

What Industry Does NBSE Operate In?

NeuBase Therapeutics operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The industry is driven by advancements in genomics, proteomics, and other areas of molecular biology, leading to the development of novel therapies for previously untreatable diseases. The competitive landscape includes established pharmaceutical companies, as well as numerous smaller biotechnology firms, all vying for market share in specific therapeutic areas. NeuBase's focus on rare genetic diseases and cancers positions it within a niche market with potentially high unmet medical needs. The global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a CAGR of 12.3% from 2023, driven by increasing demand for personalized medicine and gene therapies.

Who Are NBSE's Key Customers?

• Patients with rare genetic diseases such as Huntington's disease and myotonic dystrophy.
• Patients with cancers caused by mutations in the KRAS gene.
• Pharmaceutical companies seeking to license or acquire novel therapies.

NBSE Valuation & Market Position

With a $1.42M market cap, NeuBase Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NBSE's quantitative score of 44/100 is below the peer average of 73/100.

FY2026 estForward Outlook

Wall Street analysts project NeuBase Therapeutics, Inc. revenue of about $6.0M for fiscal 2026, with EPS near $-1.57.

F-Score 2/9Financial Health

NeuBase Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.58 places it in the distress zone, a signal of elevated financial risk.

ROE -89%Key Financial Metrics

Return on equity for NeuBase Therapeutics, Inc. stands at -88.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 5.92 indicates the company holds enough short-term assets to cover its near-term obligations.

NBSE Financials

NBSE Latest News

NBSE Analyst Consensus

NBSE MoonshotScore

Common Questions About NBSE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources